Close

Add to pipeline

Save Close
You are viewing a limited version of this profile. To access i3's full capabilities.
Pivot Bio
Save
Company logo (jpg or png)
Parent company
Edit alternate names

Short description

Developer of microbial inputs that reduce reliance on synthetic fertilizers

Founded in 2011
Founded in

Company type Private Public ()
Company type

Industry Group agriculture & food

Sector crop inputs

TRL Range 4-6
TRL 1 Basic research
TRL 2 Technology formulation
TRL 3 Applied research
TRL 4 Small scale prototype
TRL 5 Large scale prototype
TRL 6 Prototype system
TRL 7 Demonstration system
TRL 8 First of a kind commercial system
TRL 9 Full commercial application
TRL Range

Ticker

Headquarters Berkeley, CA Berkeley, United States
Address
City
State
Zip
Country

Parent Companies

Website

Updated by Cleantech Group on 08/30/2023

Traction
  • 0 M&A items
tags
Similar companies
Customers
Save
Add Customer
Date Company
Partnerships
Save
Add Partnership
Date Partner Type
03/20/2019
3Bar Biologics 3Bar Biologics
3Bar and Pivot Bio are working on a on-site microbial growing technology. They are currently marketing the product through traditional retail channels like coops. The average price is $5 per acre and the company’s field trials have shown an average yield increase of 7 to 8 bushels per acre, which equates to about $30 per acre.
View source    
Confirmed by 3Bar Biologics
Technology Partner
Delete
Investment Rounds
Save

IPO INFORMATION

Date

IPO status

IPO Type

Amount

Initial shares

Ticker symbol

Exchange listed

Prospectus URL

Prospectus

Source URL

Source

Description

Cancel Save
Add Investment
Date Investors Type Amount
07/19/2021 DCVC Data Collective DCVC Data Collective , Temasek Holdings Temasek Holdings , Generation Investment Management Generation Investment Management , G2VP G2VP , Rockefeller & Co Rockefeller & Co , Breakthrough Energy Ventures Breakthrough Energy Ventures , Continental Grain Company Continental Grain Company , Prelude Ventures Prelude Ventures , Bunge Ventures Bunge Ventures , Tekfen Ventures Tekfen Ventures (10)
Post-money valuation of
Pivot Bio said it will use the Series D capital — which takes its total funding to date to $600 million — for “rapidly scaling” its US business while expanding its global presence and releasing new products.
 Growth Equity $430,000,000
Delete
Click to add IPO information
Products
Save
Add Product
Product image Name Product status Revenue model Cost metrics
You are viewing a limited version of this profile. To access i3's full capabilities.
Back to top

Preload svg text font